Sustained Management of Chronic High Blood Pressure

Syscor (Nisoldipine) is commonly used as a long-term therapy for managing Systemic Hypertension and Chronic Stable Angina Pectoris. For chronically high blood pressure, the central therapeutic benefit contributes to providing sustained pressure control throughout the day. This supports overall cardiovascular stability and helps with addressing the risk associated with persistent pressure elevation.

---

Relief for Systemic and Ischemic Conditions

The medication plays a role in managing conditions characterized by increased physiological stress, such as hypertension and angina. For patients experiencing recurrent episodes of chest discomfort or pain, Syscor can assist with managing the frequency and intensity of these symptoms. This approach is relevant for easing symptoms that interfere with daily comfort and cause functional strain, which contributes to supporting overall physical capacity and better exercise tolerance. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Management of Anginal Chest Pain The medication is commonly used to help manage the recurrence of chest discomfort and support a patient's capacity for daily activities.

Who can and cannot use Syscor?

The population eligibility for using Syscor (Nisoldipine) is defined by official regulatory bodies, classifying patients into allowed, restricted, and contraindicated groups. This medication is approved for use in adult patients for managing systemic hypertension and chronic stable angina.

Absolute Non-Eligibility (Contraindications)

Syscor must not be used in patients with specific severe conditions, as defined in regulatory labeling. These absolute contraindications include known hypersensitivity to Nisoldipine or other dihydropyridine calcium channel blockers. Use is also prohibited for patients in cardiogenic shock, experiencing unstable angina pectoris, or those who have had a recent myocardial infarction (within the preceding four weeks).

Population Restrictions and Limitations

Official labeling specifies limitations based on age and physiological status:

• Pediatric Patients: Use in children and adolescents under 18 years of age is not established and is not recommended.
• Organ Impairment: Patients with severe hepatic impairment (severe liver disease) are subject to use restrictions due to the potential for reduced clearance.
• Reproductive Status: The medicine is not recommended for women who are pregnant or breastfeeding.
• Concomitant Use: Co-administration with strong inducers of the CYP3A4 enzyme (such as rifampin) is prohibited as it may critically reduce drug concentration.

The interaction profile for Nisoldipine (Syscor) is defined primarily by its metabolism via the CYP3A4 enzyme and the resulting pharmacokinetic changes, as documented in regulatory information. This leads to restrictions regarding co-administered medicines and specific foods.

Documented Pharmacokinetic Restrictions

Substance Category	Interaction Classification	Outcome Description
Strong CYP3A4 Inhibitors (e.g., Itraconazole, Ketoconazole)	Formal Contraindication	Co-administration is prohibited due to the risk of significant, multi-fold increases in Nisoldipine plasma concentrations (AUC and C max).
Grapefruit Juice / Products	Formal Contraindication	Inhibition of intestinal CYP3A4 causes a substantial increase in systemic drug exposure.
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin)	Avoided / Restricted Use	These agents accelerate Nisoldipine metabolism, resulting in severely reduced or undetectable drug levels, potentially leading to loss of pharmacological action.
High-Fat Meals	Administration Restriction	Must not be administered with a high-fat meal due to documented increases in the drug's peak plasma concentration.

Co-administration with Cimetidine is also documented to result in a pharmacokinetic interaction that increases Nisoldipine's AUC and C max by 30 to 45 percent. From a pharmacodynamic perspective, combining Nisoldipine with other antihypertensive agents may lead to an officially documented additive hypotensive effect. Furthermore, regulatory information notes that interactions may be more clinically relevant for patients with hepatic impairment, as this condition is an intrinsic factor altering drug clearance.

Selective T-Cell Activation Inhibition

Syscor exerts its effect by targeting a key regulatory system within the adaptive immune response. The drug enters T-lymphocytes and forms a complex with the protein cyclophilin, which then inhibits the essential enzyme calcineurin. This specific molecular interference inhibits the signal required for T-cell activation and proliferation.

Modulating Lymphokine Production Cascade

By blocking calcineurin, Syscor disrupts the subsequent gene transcription cascade, preventing a crucial factor (NF-AT) from initiating the production of vital immune messengers, such as Interleukin-2 (IL-2). The resulting reduced release of these lymphokines alters the chemical signals that support T-cell proliferation. This mechanism causes an attenuation of the T-cell-mediated immune response, altering the overall physiological profile.

Official Administration Principles of Syscor

Syscor, which contains the active ingredient Nisoldipine, is provided exclusively as an extended-release tablet for oral administration and is intended for chronic daily use. The design of this specific tablet formulation mandates strict adherence to its administration protocols to ensure the active substance is released slowly over time, supporting a sustained therapeutic effect.

---

Dosage and Frequency

The standard adult regimen involves taking the medication once daily. The usual initial dose is 17 mg, with typical maintenance doses ranging between 17 mg and 34 mg per day. Dosage adjustments are made gradually, often at weekly intervals, and the maximum daily dose generally does not exceed 51 mg once daily. For certain populations, a lower starting dose is specified: this includes older adults and patients with hepatic impairment, for whom an initial dose of 8.5 mg once daily is typically recommended. Syscor is not indicated for use in pediatric patients.

---

Intake Conditions and Tablet Handling

The extended-release tablet must be swallowed whole and should never be crushed, chewed, or divided. The timing of administration is constrained by specific rules: the medicine must be taken on an empty stomach, meaning either one hour before a meal or two hours after. Furthermore, the consumption of grapefruit juice or products must be avoided entirely when administering Syscor. If a dose is missed, the protocol is to take the next scheduled dose at the regular time and not to double the dose to compensate.

Research Evidence / Overview of Studies for Syscor

Evidence for Use in Systemic Hypertension

Research exploring Syscor's active ingredient was evaluated in Randomized Controlled Trials (RCTs), including studies comparing the ingredient to both placebo and other established blood pressure medications. These studies were applied in populations of adult patients with essential hypertension. The primary measurements monitored in these studies related to trough systolic and diastolic blood pressure (BP), as well as profiles tracked over a 24-hour period.

Studies exploring short-term changes consistently reported how blood pressure measurements evolved in the observed populations, describing patterns related to lower blood pressure readings when measured against baseline levels and compared to placebo. Research describes that a certain number of patients were observed achieving predefined target BP goals within the short-to-intermediate term of the trials.

While the evidence base describing blood pressure measurements was documented, long-term data regarding cardiovascular outcomes, such as stroke or other major adverse events, are not fully established by Nisoldipine-specific RCTs and are generally referenced from meta-analyses of the broader calcium channel blocker class.

---

Evidence for Use in Chronic Stable Angina Pectoris

The research for Syscor's active ingredient in conditions characterized by fluctuating or episodic manifestations, such as chronic stable angina, was studied for in Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity in adult patients experiencing chest discomfort. Research examined functional outcomes, including the total time patients could exercise and the duration until symptoms began during testing.

Studies focusing on episodes where symptoms become more noticeable reported how symptoms evolved in the observed populations, describing patterns related to increased time to onset of symptoms during exercise. Findings indicate that studies monitored changes in patients' ability to perform activities and evaluated the reported number of self-reported anginal episodes over the defined time intervals.

---

What Research Gaps and Uncertainty Remain

Research highlights what is known—and what is still uncertain. Long-term outcomes are not fully established regarding the definitive impact on major cardiovascular events. Findings were mixed or inconsistent in investigational research exploring use in patients with certain ventricular function issues, where certainty remains low. Furthermore, follow-up durations were limited in the angina trials, meaning the research provides context but not individual predictions of long-term symptom management.

Key Studies & References

1. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension. The South African Multicenter ANCHOR Study

Common questions about Syscor (FAQ)

---

Q: Does this medication make you sleepy?

Official product information indicates that dizziness and somnolence, which is the term for sleepiness or drowsiness, are commonly reported side effects. Patients are generally advised to use caution, such as when driving or operating machinery, until they know how the medication affects them.

---

Q: How should I take this medicine, and can I take it with food?

Regulatory instructions state that Syscor capsules are taken orally. They may be administered with or without food. Patients are typically directed to follow the specific administration guidelines provided in the official prescribing information.

---

Q: Can I drink alcohol while taking this medicine?

Official medication guides state that alcohol consumption should be avoided during treatment. The combination of Syscor and alcohol can potentially increase central nervous system side effects, such as sleepiness, dizziness, or impaired coordination.

---

Q: How should I stop taking this medication?

Regulatory documentation warns that stopping Syscor abruptly or too quickly may increase the risk of certain symptoms, including seizures, insomnia, anxiety, or nausea. The regulatory documents state that treatment is typically recommended to be tapered gradually over a period of time, such as at least one week, to reduce the risk of withdrawal symptoms.

---

Q: Can children 2 years old use it?

This medication is approved for treating specific conditions in adults and certain pediatric patients. According to official labeling, it is approved for use in pediatric patients for partial-onset seizures starting as young as 1 month of age (depending on the specific formulation). The official uses for nerve pain or fibromyalgia are not listed for patients under 18 years of age.

---

Q: What is the most serious side effect I should watch out for?

Official regulatory warnings highlight the potential for serious reactions such as Angioedema (swelling of the face, throat, or mouth), Hypersensitivity reactions, and Respiratory Depression (severe breathing problems). The official label notes that the risk of respiratory depression may be higher when Syscor is used with other central nervous system depressants or in patients with pre-existing respiratory impairment.

---

Q: Can I take this if I am pregnant or breastfeeding?

According to official product information, this medication may cause harm to a fetus. It should only be used during pregnancy if the potential benefit is deemed to outweigh the potential risk. The drug is excreted into human milk; regulatory documents recommend that breastfeeding be avoided during treatment.

Syscor (Nisoldipine) Storage and Disposal

Official Storage Conditions

Syscor extended-release tablets must be stored in a closed container at controlled room temperature. The official labeling requires strict environmental protection, mandating that the medicine be stored away from heat, moisture, and direct light, and that it be kept from freezing.

Constraint	Requirement
Temperature	Controlled room temperature
Environment	Protect from heat, moisture, and light
Freezing	Keep from freezing

Stability and Child Safety

The medicine should not be kept if it is outdated or no longer needed. For child safety, it is required to keep Syscor out of the reach of children.

Disposal Instructions

To dispose of unused or expired Syscor, the official guidance states to ask a healthcare professional how any unused medicine should be disposed of.